NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Chimerix Inc (NASDAQ: CMRX)

 
CMRX Technical Analysis
5
As on 24th Dec 2024 CMRX STOCK Price closed @ 3.34 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.01 & Strong Buy for SHORT-TERM with Stoploss of 1.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

CMRXSTOCK Price

Open 3.07 Change Price %
High 3.38 1 Day 0.32 10.60
Low 3.05 1 Week 0.39 13.22
Close 3.34 1 Month 2.30 221.15
Volume 1629309 1 Year 2.13 176.03
52 Week High 2.99 | 52 Week Low 0.77
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
LMDX 0.02 0.00%
LCID 3.20 3.23%
AVGR 1.45 126.56%
NVDA 140.22 0.39%
AKTS 0.04 0.00%
TNXP 0.39 -2.50%
PONO 1.72 2.38%
TELL 1.00 0.00%
TSLA 462.28 7.36%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
GOEV 1.46 1725.00%
CLEU 2.63 1543.75%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
BAOS 8.24 390.48%
NDRAW 0.03 200.00%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
 
NASDAQ USA Top Losers Stocks
KPLTW 0.00 -100.00%
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
TFFP 0.06 -62.50%
MILEW 0.06 -53.85%
MINM 0.15 -51.61%
LOTZW 0.01 -50.00%
 
 
CMRX
Daily Charts
CMRX
Intraday Charts
Whats New @
Bazaartrend
CMRX
Free Analysis
 
CMRX Important Levels Intraday
RESISTANCE3.98
RESISTANCE3.77
RESISTANCE3.65
RESISTANCE3.52
SUPPORT3.16
SUPPORT3.03
SUPPORT2.91
SUPPORT2.70
 
CMRX Forecast December 2024
4th UP Forecast3.82
3rd UP Forecast3.67
2nd UP Forecast3.57
1st UP Forecast3.48
1st DOWN Forecast3.2
2nd DOWN Forecast3.11
3rd DOWN Forecast3.01
4th DOWN Forecast2.86
 
CMRX Weekly Forecast
4th UP Forecast3.53
3rd UP Forecast3.47
2nd UP Forecast3.43
1st UP Forecast3.39
1st DOWN Forecast3.29
2nd DOWN Forecast3.25
3rd DOWN Forecast3.21
4th DOWN Forecast3.15
 
CMRX Forecast2024
4th UP Forecast8.43
3rd UP Forecast6.8
2nd UP Forecast5.79
1st UP Forecast4.78
1st DOWN Forecast1.9
2nd DOWN Forecast0.89
3rd DOWN Forecast-0.12
4th DOWN Forecast-1.75
 
 
CMRX Other Details
Segment EQ
Market Capital 470060832.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
CMRX Address
CMRX
 
CMRX Latest News
 
Your Comments and Response on Chimerix Inc
 
CMRX Business Profile
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina. Address: 2505 Meridian Parkway, Durham, NC, United States, 27713
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service